BARBARA ANN KARMANOS CANCER INSTITUTE

BARBARA ANN KARMANOS CANCER INSTITUTE logo
🇺🇸United States
Ownership
Private
Established
1995-01-01
Employees
5K
Market Cap
-
Website
http://www.karmanos.org

Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma

First Posted Date
2004-07-19
Last Posted Date
2013-04-05
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Registration Number
NCT00002907
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2004-06-10
Last Posted Date
2013-04-29
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
20
Registration Number
NCT00002656
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

KRN5500 in Treating Patients With Metastatic Solid Tumors

First Posted Date
2004-05-26
Last Posted Date
2014-04-25
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
27
Registration Number
NCT00002923
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

First Posted Date
2004-05-24
Last Posted Date
2013-04-09
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
40
Registration Number
NCT00002552
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Phase 2
Completed
Conditions
First Posted Date
2004-05-24
Last Posted Date
2012-08-07
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
280
Registration Number
NCT00002547
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Fenretinide in Treating Patients With Solid Tumors

First Posted Date
2004-05-21
Last Posted Date
2014-04-11
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
31
Registration Number
NCT00003250
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Phase 2
Completed
Conditions
First Posted Date
2004-04-05
Last Posted Date
2013-04-08
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Registration Number
NCT00014573
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate

First Posted Date
2004-03-09
Last Posted Date
2014-03-05
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
32
Registration Number
NCT00078923
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 2
Completed
Conditions
First Posted Date
2004-02-12
Last Posted Date
2013-04-05
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
30
Registration Number
NCT00004003
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2003-10-21
Last Posted Date
2013-04-29
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
24
Registration Number
NCT00030420
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath